| |
Control group
|
HFD group
|
Acipimox group
|
|---|
|
Weeks
|
8 w
|
16 w
|
24 w
|
8 w
|
16 w
|
24 w
|
8 w
|
16 w
|
24 w
|
|
hepatic MDA (nmol/mg)
|
1.59 ± 0.19
|
2.27 ± 0.30
|
2.41 ± 0.39
|
2.17 ± 0.21
|
5.65 ± 0.36**#
|
7.15 ± 0.51**##
|
2.01 ± 0.23
|
4.15 ± 0.28**
|
3.62 ± 0.52
|
|
hepatic GSH-Px (U/mg)
|
691.0 ± 31.2
|
674.1 ± 48.5
|
606.7 ± 36.2
|
471.5 ± 42.8*
|
463.0 ± 26.9*
|
504.4 ± 19.7
|
465.8 ± 56.4*
|
514.8 ± 45.4*
|
561.1 ± 54.6
|
- Data are shown as means ± SEM. *
p < 0.05 versus the corresponding control group; **
p < 0.01 versus the corresponding Control group; #
p < 0.05 versus the corresponding Acipimox group; ##
p < 0.01 versus the corresponding Acipimox group, HFD high-fat diet, MDA malondialdehyde, GSH-Px glutathione peroxidase
